Corbus Pharmaceuticals Holdings (CRBP) Notes Payables (2013 - 2024)
Corbus Pharmaceuticals Holdings (CRBP) recorded quarterly Notes Payables of $77000.0 in Q2 2024, down 59.43% quarter-over-quarter from $189818.0 in Q1 2024, and up 50.52% on a YoY basis from $51157.0 in Q3 2023.
Corbus Pharmaceuticals Holdings (CRBP) Notes Payables (2013 - 2024) Analysis & Trends
Corbus Pharmaceuticals Holdings' Notes Payables history runs 12 years deep, the most recent figure standing at $77000.0 for Q2 2024.
- In Q2 2024, Notes Payables rose 50.52% year-over-year to $77000.0; the TTM figure through Jun 2024 stood at $77000.0 (up 50.52% YoY), while the FY2023 annual figure was $301000.0, down 14.81% from the prior year.
- Notes Payables was $77000.0 for Q2 2024 at Corbus Pharmaceuticals Holdings, down from $189818.0 in the prior quarter.
- In the past five years, Notes Payables ranged from a high of $767938.0 in Q4 2021 to a low of $51157.0 in Q2 2023.
- Historically, Notes Payables has averaged $304141.7 across 5 years, with a median of $252129.0 in 2023.
- The sharpest annual moves came in 2020 and 2022: Notes Payables surged 74.99% in 2020, then sank 53.99% in 2022.
- A 5-year view of Notes Payables shows it stood at $710158.0 in 2020, then gained by 8.14% to $767938.0 in 2021, then tumbled by 53.99% to $353323.0 in 2022, then slipped by 14.81% to $301000.0 in 2023, then tumbled by 74.42% to $77000.0 in 2024.
- The last three Notes Payables figures came in at $77000.0 (Q2 2024), $189818.0 (Q1 2024), and $301000.0 (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - |
| 10 | Corbus Pharmaceuticals Holdings | 133.67 Mn | 105.86 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 77,000.00 |
| Mar 31, 2024 | 189,818.00 |
| Dec 31, 2023 | 301,000.00 |
| Jun 30, 2023 | 51,157.00 |
| Mar 31, 2023 | 203,258.00 |
| Dec 31, 2022 | 353,323.00 |
| Jun 30, 2022 | 110,705.00 |
| Mar 31, 2022 | 440,815.00 |
| Dec 31, 2021 | 767,938.00 |
| Jun 30, 2021 | 102,693.00 |
| Mar 31, 2021 | 408,278.00 |
| Dec 31, 2020 | 710,158.00 |
| Jun 30, 2020 | 108,936.00 |
| Mar 31, 2020 | 432,905.00 |
| Dec 31, 2019 | 752,659.00 |
| Jun 30, 2019 | 99,333.00 |
| Mar 31, 2019 | 247,384.00 |
| Dec 31, 2018 | 394,305.00 |
| Jun 30, 2018 | 83,704.00 |
| Mar 31, 2018 | 208,648.00 |